Compare
AbbVie vs TG Therapeutics (ABBV vs TGTX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and TG Therapeutics (TGTX) +75.8%; so far this year the figures are +27.5% and +100.7%.
AbbVie is the larger company by market value, about 56.2 times the size of TG Therapeutics.
On trailing earnings, ABBV trades at 50.1 times and TGTX at 21.8 times.
Revenue grew +10.7% at ABBV and +76.1% at TGTX over the last year.
ABBV yields 2.38%. TGTX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | TGTX | |
|---|---|---|
| Price | $291.31 | $59.83 |
| 1-day | +1.07% | +3.18% |
| YTD | +27.49% | +100.69% |
| 1 year | +34.39% | +75.75% |
| 3 years | +104.47% | +491.16% |
| Market cap | $514.9B | $9.2B |
| P/E | 50.1 | 21.8 |
| P/S | 7.80 | 11.45 |
| P/B | — | 15.16 |
| Revenue growth | +10.70% | +76.10% |
| EPS growth | +340.20% | +643.20% |
| Gross margin % | 73.7 | 82.4 |
| Net margin % | 15.7 | 55.2 |
| ROE % | — | 73.1 |
| Debt / equity | — | 1.23 |
| FCF yield % | 3.7 | 0.2 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.56 |
| RSI (14) | 59.7 | 58.7 |
| Technical rating |